

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Submitted for form 1449/PTO

**SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Sheet 1 of 2

Complete if Known

Application Number 09/864,078  
Filing Date 23 May 2001  
First Named Inventor Sommadossi, J-P. et al.  
Group Art Unit 1623  
Attorney Docket Number 06171.105022

RECEIVED  
JUL 07 2003  
TECHNICAL SERVICES

**U.S. PATENT DOCUMENTS**

| Examiner Initials * | Cite No. <sup>1</sup> | U.S. Patent Document |                      | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pgs, Clms, Lns, Where Relevant Passages/Relevant Figs Appear |
|---------------------|-----------------------|----------------------|----------------------|---|--|--|
|                     |                       | Number               | Kind Code (if known) |   |  |  |
| AO                  | A                     | 6,395,716            |                      | Novirio Pharmaceuticals Limited                 | 28 May 2002                                      |  |
| AO                  | B                     | 6,444,652            |                      | Novirio Pharmaceuticals Limited                 | 03 September 2002                                |  |
| AO                  | C                     | 6,340,690            |                      | Bio-Chem Pharma, Inc.                           | 02 January 2002                                  |  |

**FOREIGN PATENT DOCUMENTS**

| Examiner Initials * | Cite No. <sup>1</sup> | Foreign Patent Document |           |                                   | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document DD-MM-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T <sup>2</sup> |
|---------------------|-----------------------|-------------------------|-----------|-----------------------------------|---|--|---|----------------|
|                     |                       | Office <sup>3</sup>     | Number    | Kind Code <sup>2</sup> (if known) |   |  |   |                |
| AO                  | D                     | WO                      | 00/09531  |                                   | Novirio Pharmaceuticals Limited                 | 24 February 2000                                 |   |                |
|                     | E                     | WO                      | 01/60315  | A3                                | Shire Biochem Inc.                              | 23 August 2001                                   |   |                |
|                     | F                     | WO                      | 01/90121  |                                   | Novirio Pharmaceuticals Limited                 | 29 November 2001                                 |   |                |
|                     | G                     | WO                      | 01/91737  |                                   | Novirio Pharmaceuticals Limited                 | 29 May 2001                                      |   |                |
|                     | H                     | WO                      | 01/92282  |                                   | Novirio Pharmaceuticals Limited                 | 26 May 2001                                      |   |                |
|                     | I                     | WO                      | 01/96353  |                                   | Novirio Pharmaceuticals Limited                 | 20 December 2001                                 |   |                |
| AO                  | J                     | WO                      | 02/057287 | A2                                | Merck & Co. Inc.                                | 25 July 2002                                     |   |                |
| AO                  | K                     | WO                      | 02/057425 | A2                                | Merck & Co. Inc.                                | 25 July 2002                                     |   |                |

Examiner Signature

*[Signature]*

Date Considered

2/1/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2001 OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submitted for Form 1449/PTO

**SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Sheet 2 of 2

Complete if Known

Application Number 09/864,078  
Filing Date 23 May 2001  
First Named Inventor Sommadossi, J-P. et al.  
Group Art Unit 1623  
Attorney Docket Number 06171.105022

**FOREIGN PATENT DOCUMENTS**

| Examiner Initials * | Cite No. 1 | Foreign Patent Document |           |                        | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document DD-MM-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T <sup>4</sup> |
|---------------------|------------|-------------------------|-----------|------------------------|---|--|---|----------------|
|                     |            | Office 3                | Number    | Kind Code 2 (if known) |   |  |   |                |
| HO                  | L          | WO                      | 02/070533 | A3                     | Pharmasset LTD.                                 | 12 September 2002                                |   |                |
|                     | M          | WO                      | 02/094289 | A1                     | F. Hoffmann-La Roche AG                         | 28 November 2002                                 |   |                |
|                     | N          | WO                      | 02/100415 | A2                     | F. Hoffmann-La Roche AG                         | 19 December 2002                                 |   |                |
|                     | O          | WO                      | 02/18404  | A2                     | F. Hoffmann-La Roche AG                         | 07 March 2002                                    |   |                |
|                     | P          | WO                      | 02/32920  | A2                     | Pharmasset LTD.                                 | 25 April 2002                                    |   |                |
|                     | Q          | WO                      | 03/026675 |                        | Idenix Pharmaceuticals Inc.                     | 03 April 2003                                    |   |                |
|                     | R          | WO                      | 03/26589  |                        | Idenix Pharmaceuticals Inc.                     | 03 April 2003                                    |   |                |
|                     | S          | WO                      | 02/48165  | A2                     | Pharmasset LTD.                                 | 17 December 2001                                 |   |                |
|                     | T          | WO                      | 01/79246  |                        | Pharmasset LTD.                                 | 13 April 2001                                    |   |                |
| HO                  | U          | WO                      | 01/32153  |                        | Bio-Chem Pharma, Inc.                           | 03 November 2000                                 |   |                |

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

| Examiner Initials * | Cite No. 1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>6</sup> |
|---------------------|------------|---|----------------|
| HO                  | V          | FRANCESCO et al., Antiviral Research 58 (2003) 1-16   |                |
|                     | W          | Oral Session V: Hepatitis C Virus, Flaviviruses   |                |

Examiner Signature

*Handwritten Signature*

Date Considered

2/1/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/88A (05-90)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |   |    |   |                          |                         |
|--|---|----|---|--------------------------|-------------------------|
| Submitted for form 1449/PTO<br><b>SUPPLEMENTAL<br/>                 INFORMATION DISCLOSURE<br/>                 STATEMENT BY APPLICANT</b> |   |    |   | <b>Complete If Known</b> |                         |
|  |   |    |   | Application Number       | 09/864,078              |
|  |   |    |   | Filing Date              | 23 May 2001             |
|  |   |    |   | First Named Inventor     | Sommadossi, J-P. et al. |
|  |   |    |   | Group Art Unit           | 1614                    |
| Sheet  | 1 | of | 1 | Attorney Docket Number   | 06171.105022.           |

| U.S. PATENT DOCUMENTS  |                          |                      |                         |  |   |  |
|------------------------|--------------------------|----------------------|-------------------------|--|---|--|
| Examiner<br>Initials * | Cite<br>No. <sup>1</sup> | U.S. Patent Document |                         | Name of Patentee or Applicant of<br>Cited Document | Date of<br>Publication of<br>Cited Document<br>MM-DD-YYYY | Pgs, Clmns, Lns,<br>Where Relevant<br>Passages/Relevant<br>Figs Appear |
|                        |                          | Number               | Kind Code<br>(if known) |  |   |  |
| HO                     | A                        | 2002/0147160         | A1                      | Merck and Co. Inc.                                 | October 10, 2002  |  |
| HO                     | B                        | 2003/0060400         | A1                      | Novirio<br>(Idenix Pharmaceuticals Inc.)           | March 27, 2003  |  |

| FOREIGN PATENT DOCUMENTS |                          |                         |              |                         |   |   |   |        |
|--------------------------|--------------------------|-------------------------|--------------|-------------------------|---|---|---|--------|
| Examiner<br>Initials *   | Cite<br>No. <sup>1</sup> | Foreign Patent Document |              |                         | Name of Patentee or<br>Applicant of Cited<br>Document | Date of<br>Publication of<br>Cited Document<br>DD-MM-YYYY | Pages,<br>Columns,<br>Lines, Where<br>Relevant<br>Passages or<br>Relevant<br>Figures Appear | T<br>6 |
|                          |                          | Office <sup>2</sup>     | Number       | Kind Code<br>(if known) |   |   |   |        |
| HO                       | C                        | WO                      | 03/051899 A1 | A1                      | Ribapharm Inc.  | 26-06-2003  |   |        |

|                       |                    |                    |        |
|-----------------------|--------------------|--------------------|--------|
| Examiner<br>Signature | <i>April Closs</i> | Date<br>Considered | 2-1-04 |
|-----------------------|--------------------|--------------------|--------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation numbers. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.